Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1995 1
1996 1
1997 1
2002 1
2003 1
2004 1
2005 2
2006 3
2007 3
2008 4
2009 7
2010 6
2011 4
2012 4
2013 12
2014 5
2015 10
2016 9
2017 9
2018 9
2019 9
2020 13
2021 27
2022 23
2023 20
2024 22
2025 24
2026 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Bhatt DL, et al. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415628 Clinical Trial.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Pitt B, et al. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449181 Clinical Trial.
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2023 May;13(2_suppl):568S-591S. doi: 10.1177/21925682231173597. Global Spine J. 2023. PMID: 37222100 Free PMC article. No abstract available.
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2025 May;15(2_suppl):793S-822S. doi: 10.1177/21925682251336882. Epub 2025 May 21. Global Spine J. 2025. PMID: 40397527 Free PMC article. No abstract available.
Diamond rotors.
Golota NC, Fredin ZP, Banks DP, Preiss D, Bahri S, Patil P, Langford WK, Blackburn CL, Strand E, Michael B, Dastrup B, Nelson KA, Gershenfeld N, Griffin R. Golota NC, et al. J Magn Reson. 2023 Jul;352:107475. doi: 10.1016/j.jmr.2023.107475. Epub 2023 May 6. J Magn Reson. 2023. PMID: 37224586 Free PMC article.
The fabrication protocol we report involves novel laser micromachining and produced rotors that presently spin at omega(r)/2pi = 111.000 0.004 kHz, with stable spinning up to 124 kHz, using N(2) gas as the driving fluid. We present the first proton-detected (13)C/(15) …
The fabrication protocol we report involves novel laser micromachining and produced rotors that presently spin at omega(r)/2pi = 111.000 0 …
An oral heme oxygenase inhibitor targets immunosuppressive perivascular macrophages in preclinical models of cancer.
Bahri M, Al-Adhami T, Demirel E, Sarkar J, Feehan KT, Anstee JE, Cheung TS, Sosnowska D, Woodman CA, Macmorland W, Yang DD, Rosekilly J, Gitsaki-Taylor R, Gillett CE, Scudamore CL, Spicer J, Rahman KM, Arnold JN. Bahri M, et al. Sci Transl Med. 2025 Aug 6;17(810):eads3085. doi: 10.1126/scitranslmed.ads3085. Epub 2025 Aug 6. Sci Transl Med. 2025. PMID: 40768602 Free PMC article.
UK Foot and Ankle Thromboembolism (UK-FATE).
Mangwani J, Houchen-Wolloff L, Malhotra K, Booth S, Smith A, Teece L, Mason LW; UK FATE Collaborative; UK FATE Collaborative; Shaikh R, Alfred W, Okhifun I, Cinar E, Bua N, Vemulapalli K, Acharya A, Gadd R, Money-Taylor J, Kantharaju R, Bhosale A, Bahri S, Broadbent R, Drummond I, Jones N, Shah S, Ravindrarjah T, Yasen Z, Singh K, Al-Habs R, Jeyaseelan L, Habbiba A, Walker T, Dewhurst M, Glasgow N, Eze D, Carter G, Rajan P, Patil V, Amer O, Malik K, Pavanerathan P, Mallick A, Seferiadis I, Currall V, Sadasivan P, Kumar S, Sanjani SR, Ciaccio M, Ayyaswamy B, Prasad P, Anand M, Sunilraj D, Lane S, Prathap S, Kankate R, Aktselis I, Davda K, Vijapur A, Tayyem M, Chau J, Azhar MS, Sturdee S, Hussain H, Sonde S, Luqman MQ, Farooq R, Wells G, Shenolikar A, Simons M, Hodgson P, Thomas R, Stevens S, Elhassan Y, Adeniyi A, Aspinall W, Joseph V, Day M, Tong A, Joyner C, Alzaranky M, Elhassan O, Chhantyal K, Arora A, Abiddin Z, Kucharski R, Ahmad I, Zeb J, Ishaq U, Thomas J, Jain K, Deol R, Faroug R, Johal K, Mordecai S, Argyropouos M, Chawla A, Ibrahim M, Pereira M, Barr L, Julies E, Hill F, Kapoor S, Bailey J, Mukhopadhyay I, Rana S, Tarig H, Qualaghassi M, Seewoonarian S, Rose B, Crate G, … See abstract for full author list ➔ Mangwani J, et al. Bone Joint J. 2024 Nov 1;106-B(11):1249-1256. doi: 10.1302/0301-620X.106B11.BJJ-2024-0128.R1. Bone Joint J. 2024. PMID: 39481430
Overall, 11,363 patients were available for analysis: 44.79% were elective (n = 5,090), 42.16% were trauma excluding TA ruptures (n = 4,791), 3.50% were acute diabetic procedures (n = 398), 2.44% were TA ruptures undergoing surgery (n = 277), and 7.10% …
Overall, 11,363 patients were available for analysis: 44.79% were elective (n = 5,090), 42.16% were trauma excluding TA ruptures ( …
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.
Mertens LJ, Koslowski M, Betzler F, Brand M, Evens R, Kärtner L, Jungaberle A, Jungaberle H, Majic T, Schmitz CN, Ströhle A, Scharf D, Spangemacher M, Wolff M, Assadi Z, Bahri S, Becher L, Färber LV, Kirchen N, Kulakova E, Kunz L, Meijer A, Rohrmoser B, Wellek S, Berger MM, Gründer G. Mertens LJ, et al. JAMA Psychiatry. 2026 May 1;83(5):448-460. doi: 10.1001/jamapsychiatry.2026.0132. JAMA Psychiatry. 2026. PMID: 41848690 Free PMC article. Clinical Trial.
RESULTS: A total of 144 participants (mean [SD] age, 42.6 [10.8] years; 85 male [59.0%]) were randomized, and 142 were included in the primary efficacy analysis: psilocybin, 25 mg (n = 47), psilocybin, 5 mg (n = 48), and nicotinamide (n = 47). Response rates …
RESULTS: A total of 144 participants (mean [SD] age, 42.6 [10.8] years; 85 male [59.0%]) were randomized, and 142 were included in the prima …
232 results